Latest Period
Q4 2025
Security Snapshot
AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL) Institutional Ownership
CUSIP: 00288U106
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
145
Shares (Excl. Options)
108,415,371
Price
$3.42
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares, no par value per share
- Symbol
- ABCL on Nasdaq
- Shares outstanding
- 305,667,944
- Price per share
- $3.66
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 108,415,371
- Total reported value
- $370,606,742
- % of total 13F portfolios
- 0%
- Share change
- +4,111,192
- Value change
- -$10,167,392
- Number of holders
- 145
- Price from insider filings
- $3.66
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ABCL - AbCellera Biologics Inc. - Common Shares, no par value per share is tracked under CUSIP 00288U106.
- 145 institutions reported positions in Q4 2025.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 145 to 97 between Q4 2025 and Q1 2026.
- Reported value moved from $370,606,742 to $192,909,940.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 145 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 00288U106?
CUSIP 00288U106 identifies ABCL - AbCellera Biologics Inc. - Common Shares, no par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00288U106:
Significant Owners of AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 11% | $120,824,425 | 33,012,138 | Baker Bros. Advisors LP | 30 Apr 2026 | |||
| BAILLIE GIFFORD & CO | 4.4% | $32,881,493 | 12,894,703 | BAILLIE GIFFORD & CO | 30 Sep 2024 |
As of 31 Dec 2025, 145 institutional investors reported holding 108,415,371 shares of AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL). This represents 35% of the company’s total 305,667,944 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 9% | 27,525,640 | 0% | 0.55% | $94,137,689 |
| Capital World Investors | 4.4% | 13,361,096 | 0% | 0.01% | $45,694,948 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.6% | 7,876,629 | 0.01% | $26,938,071 | |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 5,810,985 | +12% | 0.03% | $19,873,569 |
| TWO SIGMA ADVISERS, LP | 1.6% | 4,878,000 | +1.6% | 0.03% | $16,682,760 |
| GOLDMAN SACHS GROUP INC | 1.4% | 4,344,485 | +1636% | 0% | $14,858,139 |
| ArrowMark Colorado Holdings LLC | 1.3% | 4,105,095 | 0% | 0.31% | $14,039,425 |
| BlackRock, Inc. | 1.3% | 3,865,896 | +6.2% | 0% | $13,221,366 |
| Driehaus Capital Management LLC | 1.2% | 3,771,999 | +118% | 0.09% | $12,900,237 |
| MORGAN STANLEY | 0.98% | 3,001,850 | +7.5% | 0% | $10,266,329 |
| BANK OF AMERICA CORP /DE/ | 0.86% | 2,632,872 | +8.9% | 0% | $9,004,422 |
| RENAISSANCE TECHNOLOGIES LLC | 0.78% | 2,389,229 | -29% | 0.01% | $8,171,163 |
| UBS Group AG | 0.63% | 1,939,409 | -22% | 0% | $6,632,778 |
| CITADEL ADVISORS LLC | 0.6% | 1,834,508 | +82% | 0% | $6,274,017 |
| TUDOR INVESTMENT CORP ET AL | 0.59% | 1,796,010 | +146% | 0.03% | $6,142,354 |
| Guardian Partners Inc. | 0.58% | 1,786,414 | 0% | 0.47% | $5,819,229 |
| MILLENNIUM MANAGEMENT LLC | 0.58% | 1,773,539 | -27% | 0% | $6,065,503 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.5% | 1,524,563 | +7.5% | 0.01% | $5,214,005 |
| JANE STREET GROUP, LLC | 0.46% | 1,397,088 | +252% | 0.01% | $4,778,041 |
| Point72 Asset Management, L.P. | 0.32% | 976,507 | 0.01% | $3,339,654 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.23% | 695,796 | +170% | 0.01% | $2,379,622 |
| STATE STREET CORP | 0.23% | 694,114 | +3.4% | 0% | $2,373,870 |
| HRT FINANCIAL LP | 0.18% | 548,431 | +26% | 0.01% | $1,875,000 |
| Intellectus Partners, LLC | 0.17% | 523,383 | -3.6% | 0.35% | $1,789,969 |
| STATE OF MICHIGAN RETIREMENT SYSTEM | 0.13% | 400,000 | 0% | 0.01% | $1,368,000 |
Institutional Holders of AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 55,221,891 | $192,909,940 | +$47,053,348 | $3.49 | 97 |
| 2025 Q4 | 108,415,371 | $370,606,742 | -$10,167,392 | $3.42 | 145 |
| 2025 Q3 | 104,032,627 | $524,646,193 | +$3,617,959 | $5.03 | 140 |
| 2025 Q2 | 107,623,463 | $370,594,083 | -$42,109,114 | $3.43 | 127 |
| 2025 Q1 | 124,693,841 | $278,605,461 | +$21,793,003 | $2.23 | 127 |
| 2024 Q4 | 113,909,183 | $333,909,974 | +$23,930,958 | $2.93 | 145 |
| 2024 Q3 | 105,626,999 | $274,569,746 | -$27,524,912 | $2.60 | 139 |
| 2024 Q2 | 114,251,365 | $337,827,363 | -$12,985,717 | $2.96 | 146 |
| 2024 Q1 | 120,885,782 | $546,343,961 | +$6,435,245 | $4.53 | 153 |
| 2023 Q4 | 119,177,804 | $681,087,686 | -$3,743,767 | $5.71 | 141 |
| 2023 Q3 | 120,025,395 | $551,791,208 | -$29,473,838 | $4.60 | 137 |
| 2023 Q2 | 124,831,655 | $809,068,808 | -$42,715,484 | $6.46 | 167 |
| 2023 Q1 | 130,072,488 | $980,706,858 | +$9,956,814 | $7.54 | 181 |
| 2022 Q4 | 138,959,875 | $1,408,301,843 | +$64,970,441 | $10.13 | 198 |
| 2022 Q3 | 132,080,272 | $1,309,587,378 | +$125,586,082 | $9.89 | 185 |
| 2022 Q2 | 117,984,795 | $1,259,732,308 | +$77,596,210 | $10.65 | 160 |
| 2022 Q1 | 113,127,329 | $1,100,172,856 | -$30,931,776 | $9.75 | 126 |
| 2021 Q4 | 114,533,051 | $1,628,519,417 | +$98,165,187 | $14.30 | 120 |
| 2021 Q3 | 98,697,276 | $1,977,505,786 | +$155,909,310 | $20.04 | 115 |
| 2021 Q2 | 90,556,840 | $1,986,081,198 | +$169,321,459 | $22.00 | 111 |
| 2021 Q1 | 71,121,706 | $2,415,006,720 | +$64,105,935 | $33.96 | 82 |
| 2020 Q4 | 68,103,635 | $2,740,470,000 | +$2,587,818,000 | $40.24 | 58 |